Patents Examined by Lakia J Jackson-Tongue
  • Patent number: 11351252
    Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: June 7, 2022
    Assignee: SNIPR Technologies Limited
    Inventor: Jasper Clube
  • Patent number: 11338000
    Abstract: Provided is a use of Butyribacter intestini in preventing and/or treating inflammation-related diseases. Specifically, in the present disclosure, it was firstly discovered that Butyribacter intestini has the function of preventing and/or treating inflammation-related diseases (for example, inflammatory bowel disease, such as ulcerative colitis, gastritis, and common enteritis; and rheumatoid arthritis).
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: May 24, 2022
    Assignee: BGI SHENZHEN
    Inventors: Yuanqiang Zou, Liang Xiao, Xiaoping Li, Jinghong Yu, Chuan Liu
  • Patent number: 11332751
    Abstract: The present disclosure includes methods and components for production of valuable industrial compounds in yeast. In an embodiment, the present invention provides a nucleic acid construct with increased stability for gene expression or gene editing comprising: a nucleic acid sequence encoding one or more of SEQ ID NO: 1-8 (CENs 1-8); and one or more regulatory elements functional in a yeast cell. In an embodiment of the present invention the nucleic acid constructs are vectors, preferably episomal vectors. High expression promoters, as well as methods for increasing production of compounds such as aromatics are disclosed.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: May 17, 2022
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Zengyi Shao, Mingfeng Cao, Miguel Suastegui, Meirong Gao
  • Patent number: 11324739
    Abstract: Novel combination therapies involving nitroxoline, its analogue or pharmaceutically acceptable salt thereof with at least one additional anti-cancer chemotherapy or immunotherapy agent are described. Related kits, pharmaceutical compositions and methods of production arlinee also described.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 10, 2022
    Assignee: Jiangsu Yahong Meditech Co., Ltd.
    Inventors: Ke Pan, Peng Huang, Qiang Li
  • Patent number: 11324814
    Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: May 10, 2022
    Assignee: Protein Potential, LLC
    Inventors: Yun Wu, Dennis J. Kopecko, B. Kim Lee Sim, Stephen L. Hoffman
  • Patent number: 11311581
    Abstract: The present invention relates to the combination of spirulina and palmitoylethanolamide (PEA) and/or pharmaceutically acceptable derivates or salts thereof, pharmaceutical formulations comprising the combination of spirulina and PEA and/or pharmaceutically acceptable derivates or salts thereof, optionally together with at least one physiologically acceptable excipient, and the use of the combination of spirulina and PEA and/or pharmaceutically acceptable derivates or salts thereof and formulations which include the said combination, for use in the prevention and/or treatment of tissue hyperactivation states, in the prevention and/or treatment of inflammatory pathologies, in the prevention and/or treatment of alterations in cardiac and/or coronary tissue, in the prevention and/or treatment of alterations in the vascular tissue, in the prevention and/or treatment of ophthalmic pathologies, preferably in the prevention and/or treatment of macular degeneration pathologies and glaucoma, in the prevention and/or tr
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: April 26, 2022
    Assignee: AGAIN LIFE ITALIA SRL
    Inventors: Raffaele Migliaccio, Carmela Migliaccio, Antonella Sardei
  • Patent number: 11298385
    Abstract: The present invention relates to a microorganism for drug delivery, which has been transformed with a gene construct comprising a therapeutically active peptide, which can be delivered safely into the intestines through oral administration, and which can express and secrete the therapeutic peptide in the gastrointestinal tract, and also relates to a pharmaceutical composition for prevention or treatment of gastrointestinal disease, which includes the same. The present invention is directed to a lactic acid bacteria drug delivery system capable of overexpressing and secreting a lactic acid bacteria-derived anticancer protein, which is developed by introducing the anticancer protein into a lactic acid bacteria expression and secretion system. It is expected that the lactic acid bacteria drug delivery system will be widely used as a natural protein therapeutic agent against gastrointestinal disease in the medical field.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: April 12, 2022
    Assignee: Cell Biotech Co., Ltd.
    Inventor: Myung Jun Chung
  • Patent number: 11291723
    Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: April 5, 2022
    Assignee: SNIPR Technologies Limited
    Inventor: Jasper Clube
  • Patent number: 11291695
    Abstract: The present invention provides a Bacillus subtilis strain selected from the group consisting of a) the strain deposited as DSM32324, b) the strain deposited as DSM32325, and c) a mutant strain of (a) or (b) which has sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline, and chloramphenicol; and has inhibitory activity against E. coli and Clostridium perfringens. The invention further relates to Bacillus compositions comprising at least one Bacillus subtilis strain of the invention, preferably the Bacillus subtilis strain DSM32324 and/or the Bacillus subtilis strain DSM32325, as Direct Fed Microbial (DFM), premix, animal feed additive or animal feed.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: April 5, 2022
    Assignee: CHR. HANSEN A/S
    Inventors: Dorthe Sandvang, Tina Styrishave
  • Patent number: 11278578
    Abstract: Combinations of probiotic compositions are described which are beneficial for human hosts in reducing gas and bloating, stomach acidity, and constipation also capable of boosting the immune capacity. The compositions comprise blends including B. coagulans, B. subtilis, and B. clausii in combination with magnesium stearate, magnesium hydroxide, and simethicone. The combination probiotic compositions of the present invention behave in a synergistic manner in their nature of action both in-vitro and in-vivo. The combination probiotic compositions of the present invention are also very stable for comparatively greater amounts of time period.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: March 22, 2022
    Assignee: Sanzyme Biologics Private Limited
    Inventors: Raunak Jay Soman, Venkat Swamy Malisetty
  • Patent number: 11248213
    Abstract: Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: February 15, 2022
    Assignee: The Regents of the University of California
    Inventors: Richard Klemke, Huawei Wang
  • Patent number: 11248040
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 15, 2022
    Assignee: TRELLIS BIOSCIENCE, LLC
    Inventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
  • Patent number: 11230594
    Abstract: It is provided novel anti-galactofuranose antibodies and their use for diagnosis of and/or treating aspergillosis, and for the design of chimeric antigen receptor T-cells, wherein single chain variable fragment of the antibodies, such as a heavy chain variable region or a light chain variable region, is fused via a spacer and a transmembrane domain to a signaling endodomain to generate an expression cassette that will be integrated into a T cell.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: January 25, 2022
    Assignees: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Donald Christopher Sheppard, Benjamin Alfred William Rufus Ralph, Todd Lambert Lowary, Susmita Sarkar, Amira Ibrahim Aly Mohamed Khalil
  • Patent number: 11214600
    Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa). Further aspects relate to immunogenic compositions comprising at least one Staphylococcal coagulase R Domain, wherein the R Domain is 80% identical in sequence to a R Domain.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 4, 2022
    Assignees: The University of Chicago, Janssen Pharmaceuticals, Inc.
    Inventors: Dominique Missiakas, Olaf Schneewind, Carla Emolo, Lena Thomer, Molly McAdow, Jeroen Geurtsen, Mark De Been
  • Patent number: 11213553
    Abstract: Disclosed is the hypolipidemic potential of Bacillus coagulans. More specifically the invention discloses the cholesterol lowering potential of Bacillus coagulans MTCC 5856 and therapeutic/biological indications thereof.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: January 4, 2022
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali, Shaheen Majeed
  • Patent number: 11207376
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: December 28, 2021
    Assignee: Second Genome, Inc.
    Inventors: Andrew Wonhee Han, Andrew Whitman Goodyear, Tarunmeet Gujral, Todd Zachary Desantis, Karim Dabbagh, Toshihiko Takeuchi, Ye Jin, Michi Izumi Willcoxon, Stefanie Banas
  • Patent number: 11198707
    Abstract: There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: December 14, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Normand Blais, Steve Labbe, Jan Poolman
  • Patent number: 11167021
    Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting piglets having maternally derived anti-Streptococcus suis antibodies against Streptococcus suis, by administering the vaccine to the piglets at an age of at most 28 days, preferably before the piglets are weaned.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: November 9, 2021
    Assignee: Intervet Inc.
    Inventor: Antonius Arnoldus Christiaan Jacobs
  • Patent number: 11155632
    Abstract: An anti-CD47 monoclonal antibody and use thereof. The provided anti-CD47 monoclonal antibody can effectively inhibit tumor growth. Blocking human SIRP and human CD47 signals may enhance macrophage phagocytosis of tumor cells, prevent the tumor cells from escaping a tumor immune defense system, and have an anti-tumor function. Blocking association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface may block a “do not eat me” signal from the tumor cells, promoting tumor cell recognition and uptake of macrophages, and thereby facilitating tumor cells to be phagocytosed. The association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface is a common “do not eat me” signal. The anti-CD47 antibody, as a very promising target in the tumor immune system, will play a powerful and effective role in human cancer therapy.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: October 26, 2021
    Assignee: CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD.
    Inventors: Xiao Feng, Lei Jin, Liang Xiao, Tao Wang, Suofu Qin
  • Patent number: 11149288
    Abstract: The present invention relates to the field of molecular biology and cell biology. More specifically, the present invention relates to a CRISPR-CAS system for a lipolytic yeast host cell.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: October 19, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Bernard Meijrink, René Verwaal, Bianca Elisabeth Maria Gielesen, Johannes Andries Roubos